Merck Posts Better-Than-Expected Second-Quarter Results on Keytruda Strength

3-line summary

• Merck reported Q2 revenue of $16.61 billion, up 5% year-over-year and above analyst estimates of $16.36 billion, and raised its 2026 revenue forecast to $66.3-$67.3 billion, according to the report.
• Keytruda sales rose 5% to $8.37 billion, beating estimates of $8.07 billion, while the company posted a quarterly loss of 13 cents per share due to a $5.7 billion charge from its Terns Pharmaceuticals acquisition, per the report.

This summary is our own processing of the source article; see the source link below for full context.